Home NDC 68151-5755 Namenda
Product NDC 68151-5755
11-digit product format 681515755
Labeler code 68151
Product ID 68151-5755_3a73e786-fa25-4c07-af56-2b4022b2cd2e
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name memantine hydrochloride
Dosage form CAPSULE, EXTENDED RELEASE
Route ORAL
Labeler Carilion Materials Management
Application NDA022525
Marketing category NDA
Marketing start 2011-10-31
Marketing end 0000-00-00
Substance MEMANTINE HYDROCHLORIDE
Active strength 14 mg/1
Pharmacologic classes NMDA Receptor Antagonists [MoA],N-methyl-D-aspartate Receptor Antagonist [EPC]
NDC exclude flag E
Listing certified through 2018-12-31
Current FDA listing Historical FDA.report record Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N022525-001 NAMENDA XR MEMANTINE HYDROCHLORIDE 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 N022525-002 NAMENDA XR MEMANTINE HYDROCHLORIDE 14MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 N022525-003 NAMENDA XR MEMANTINE HYDROCHLORIDE 21MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 N022525-004 NAMENDA XR MEMANTINE HYDROCHLORIDE 28MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21
Orange Book patents# Current patent rows page 1 of 1 · 8 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N022525-001 8039009 2029-03-24 U-539 2011-11-16 N022525-001 8039009*PED 2029-09-24 Pediatric extension N022525-002 8039009 2029-03-24 U-539 N022525-002 8039009*PED 2029-09-24 Pediatric extension N022525-003 8039009 2029-03-24 U-539 N022525-003 8039009*PED 2029-09-24 Pediatric extension N022525-004 8039009 2029-03-24 U-539 N022525-004 8039009*PED 2029-09-24 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-01 22:54:32 2026-06 N022525-001 NAMENDA XR 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-002 NAMENDA XR 14MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-003 NAMENDA XR 21MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-004 NAMENDA XR 28MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CAPSULE, EXTENDED RELEASE / ORAL RLD 2010-06-21 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-01 22:54:32 2026-06 N022525-001 8039009 2029-03-24 U-539 2011-11-16 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-001 8039009*PED 2029-09-24 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-002 8039009 2029-03-24 U-539 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-002 8039009*PED 2029-09-24 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-003 8039009 2029-03-24 U-539 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-003 8039009*PED 2029-09-24 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-004 8039009 2029-03-24 U-539 a50c72e98297…2026-08-01 22:54:32 2026-06 N022525-004 8039009*PED 2029-09-24 Pediatric extension a50c72e98297…
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 68151-5755-8 Namenda XR 1 in 1 CUP CAPSULE, EXTENDED RELEASE 1 6
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 68151-5755 NAMENDA XR (MEMANTINE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE NAMENDA XR (MEMANTINE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [CARILION MATERIALS MANAGEMENT] 6 Legacy NDC, 1 package rows 20180228_1fa2b7bc-94e5-4566-a7c5-419f8fd393a7.zip
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Status 68151-5755-8 68151575508 1 in 1 CUP Historical